During Thursday’s Current trade, Shares of Himax Technologies, Inc. (ADR) (NASDAQ:HIMX), lost -1.35% to $7.30.
Himax Technologies, Inc. (HIMX) a leading supplier and fabless manufacturer of display drivers and other semiconductor products, declared that the Company will attend the Oppenheimer 18th Annual Technology, Internet & Communications Conference from August 11-12, 2015 at the Four Seasons Hotel in Boston.
Himax Technologies, Inc., a fabless semiconductor company, provides display imaging processing technologies to consumer electronics worldwide. The company operates through Driver IC and Non-Driver Products segments. It offers display driver integrated circuits (ICs) and timing controllers used in televisions (TVs), laptops, monitors, mobile phones, tablets, digital cameras, car navigation, and other consumer electronics devices. Shares of Royal Caribbean Cruises Ltd (NYSE:RCL), declined -1.22% to $82.89, during its current trading session.
Royal Caribbean Cruises Ltd. (RCL) has planned a conference call for 10:00 a.m. Eastern Daylight Time, Friday, July 31, 2015, to talk about the company’s second quarter 2015 financial results. The call will be accessible on-line at the company’s investor relations website, www.rclinvestor.com. To listen to the call by phone, please dial (877) 663-9606 in the US and Canada. International phone calls should be made to (706) 758-4628. There is no passcode or meeting number. A replay of the webcast will be accessible at the same site for a month following the call.
Royal Caribbean Cruises, Ltd. operates as a cruise company. The company operates cruisers under the Royal Caribbean International, Celebrity Cruises, Pullmantur, Azamara Club Cruises, CDF Croisières de France, and TUI Cruises brand names. The Royal Caribbean International brand provides cruise itineraries ranging from 2 to 18 nights with options for onboard dining, entertainment, and other onboard activities to various destinations.
RXi Pharmaceuticals Corp (NASDAQ:RXII), during its Thursday’s current trading session decreased -2.44% to $0.423.
RXi Pharmaceuticals Corp (RXII) declared that it received two Notices of Allowance from the United States Patent and Trademark Office (USPTO). One is on RXi’s novel, self-delivering RNAi platform (sd‑rxRNA®). The patent, titled “Reduced Size Self-Delivering RNAi Compounds,” covers both the composition and methods of use of RXi’s self-delivering platform. The patent, once issued, will be planned to expire in 2031.
In addition, RXi declared that it has also received a Notice of Allowance from the USPTO covering the composition and methods of use for rxRNAori® compounds targeting Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). These compounds may be beneficial for the treatment of inflammatory diseases and/or metabolic diseases. RXi’s rxRNAori platform are highly potent RNAi compounds which require delivery vehicles to be taken up by cells and tissues of interest. The patent, once issued, will be planned to expire in 2029.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs comprise RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, in addition to for the administration of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma.
Finally, Verisign, Inc. (NASDAQ:VRSN), decreased -0.37%, to $70.28.
VeriSign, Inc. (VRSN), a global leader in domain names and Internet security, stated financial results for the second quarter of 2015.
Second Quarter GAAP Financial Results
VeriSign, Inc. and auxiliaries (“Verisign”) stated revenue of $263 million for the second quarter of 2015, up 4.9 percent from the same quarter in 2014. Verisign stated net income of $93 million and diluted earnings per share of $0.70 for the second quarter of 2015, contrast to net income of $100 million and diluted EPS of $0.71 in the same quarter in 2014. The operating margin was 56.7 percent for the second quarter of 2015 contrast to 57.2 percent for the same quarter in 2014.
Second Quarter Non-GAAP Financial Results
Verisign stated, on a non-GAAP basis, net income of $99 million and diluted EPS of $0.74 for the second quarter of 2015, contrast to net income of $96 million and diluted EPS of $0.68 for the same quarter in 2014. The non-GAAP operating margin was 61.3 percent for the second quarter of 2015 contrast to 60.9 percent for the same quarter in 2014. A table reconciling the GAAP to the non-GAAP results (which excludes items described below) is appended to this release.
VeriSign, Inc. provides domain name registry services and Internet security worldwide. The company offers registry services that operate the authoritative directory of .com, .net, .cc, .tv, and .name domain names, in addition to the back-end systems for .gov, .jobs, .edu domain names, and others. Its registry services allow individuals and organizations to establish their online identities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.